
Latest Findings in the Pharmacological Treatment of ADHD – Aligned with Canadian (CADDRA) Standards (2026 Update)
CADDRA’s May 2026 Medication Chart still places long-acting psychostimulants first-line for ADHD in Canada, with practical dosing, second-line non-stimulants, and notes on newer agents such as centanafadine.


